Previous close | 12.20 |
Open | 12.20 |
Bid | 12.70 |
Ask | 13.70 |
Strike | 22.50 |
Expiry date | 2025-01-17 |
Day's range | 12.20 - 12.20 |
Contract range | N/A |
Volume | |
Open interest | 5 |
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest quarterly report and things are not looking great...